tbuckley/cabot-search huggingface dataset:
Binding and Retrieval in Action Control (BRAC)
Authors: Christian Frings, Bernhard Hommel, Iring Koch, Klaus Rothermund, David Dignath, Carina Giesen, Andrea Kiesel, Wilfried Kunde, Susanne Mayr, Birte Moeller, Malte Möller, Roland Pfister, Andrea Philipp
Journal: Trends in Cognitive Sciences (2020)

Human action control relies on representations that integrate perception and action, but the relevant research is scattered over various experimental paradigms and the theorizing is overly paradigm-specific. To overcome this obstacle we propose BRAC (binding and retrieval in action control), an overarching, integrative framework that accounts for a wide range of seemingly unrelated findings by assuming 'two core processes: feature binding and retrieval'. In contrast to previous approaches, we define binding and retrieval as functionally different and separable processes that independently contribute to the observed effects. Furthermore, both processes are independently modulated by top-down and/or bottom-up processes. BRAC organizes the literature on action control in novel ways, and relates diverse independently investigated action-related phenomena from different research fields to each other.
Analysis of preclinical and clinical data on the role of hyperthermia with gemcitabine and carboplatin on pancreatic adenocarcinoma
Authors: S. O. Peters, A. S. Stoltz, A. Bakshandeh, M. Vollmert, T. Wagner
Journal: Journal of Clinical Oncology (2006)

14123 Background: Preclinical data show synergism of whole body hyperthermia (HT) of 41.8°C with gemcitabine (G) and carboplatin (CP) in lung head and neck tumor cell lines. Advanced pancreatic adenocarcinoma is an aggressive disease and is associated with high morbidity and a median survival of 8 to 12 months. The role of whole body HT with G and CP in the treatment of pancreatic cancer is unknown. Methods: We first show preclinical data to study the effects of combining HT of 37°, 39°, 41.8 and 43°C for 1 h with G and CP on the human pancreas carcinoma cell line DAN-G. We assessed proliferation ratios using crystal-violett assays and cell cycles by flow cytometry. We secondly analyzed the clinical outcome of 13 pts that received whole body HT of 41.8°C with G and CP for advanced pancreatic cancer on a compassionate-use basis at our institution between 2000 to 2004 was assessed for toxicity, response and overall survival. Results: Preclinical studies showed no effects of HT of 37, 39 and 41.8°C on DAN-G cell proliferation and cell cycle behaviour when used alone without cytostatic drugs. At 43°C cells decompose (in all experiments). Additional G and/or CP at concentrations of IC50 to HT of 37, 39, 41, 8°C did not alter the effects of the drugs alone. Cell cycle anaylsis showed that an increment of temperatures did not effect cycle phases. Analysis of the clinical data of patients whole body HT with G and CP showed partial remissions in 3 pts (23%) and no change situations in 5 pts (38%). Of 13 pts received only 2 cycles because of disease progression (n = 5) or because they refused to further treatment due to minor toxicities. 4 pts received all 4 therapy cycles initially planned. Overall survival was 11.4 months, one year survival for all patients was 38%. Generally the treatment was well tolerated. Grade 3–4 toxicities were thrombocytopenia in one patient and therapy induced anemia and neutropenia in another patient occurring after the forth cycle of treatment. Conclusions: Preclinical and clinical data show that HT plus G and CP is of no benefit in the treatment of pancreatic cancer. No significant financial relationships to disclose.
IMPACT OF PREOPERATIVE ATRIAL FIBRILLATION/FLUTTER IN LEFT VENTRICULAR ASSIST DEVICE RECIPIENTS
Authors: John-Ross Clarke, Cesar Caraballo, Neal Ravindra, Paul Miller, Megan McCullough, Catherine Mezzacappa, Clancy Mullan, Juliana Lawrence, Fouad Chouairi, Nihar R. Desai, James Freeman, Tariq Ahmad, Daniel J. Friedman
Journal: Journal of the American College of Cardiology (2020)
Primary breast cancer tryptase expression as novel molecular drug target.
Authors: Girolamo Ranieri, Michele Ammendola, Mario Brandi, Andrea Misino, Veronica Goffredo, Rosa Patruno, Valentina Di Lecce, Caldarola Gennaro Gadaleta, Giovambattista De Sarro, Rosario Sacco, Cosmo Damiano Gadaleta
Journal: Journal of Clinical Oncology (2012)

e21113 Background: Tryptase, a serine protease stored and released from mast cells granules has been identified as a new non-classical angiogenetic factor. Mast cells can release tryptase following c-Kit receptor activation. We have evaluated the correlations among the number of MCs positive to tryptase (MCDPT), the number of c-Kit receptor expressing cells (C-KREC) and microvascular density (MVD) in a series of 88 primary T1-3, N0-2 M0 female breast cancer by means of immunohistochemistry and image analysis methods. Methods: Six-micrometers thick serial sections of formalin-fixed and paraffin-embedded bioptic tumor samples were microwaved at 500 W for 10 min. and treated with a 3% hydrogen peroxide solution. Sections were incubated with primary antibodies: anti-tryptase (AA1; Dako, Glostrup, Denmark), anti-c-Kit receptor (A4502;Dako, Glostrup, Denmark) and anti-CD34 (QB-END 10; Bio-Optica Milan, Italy). In serial sections MVD, MCDPT and C-KREC were counted by means of image analysis at x400. Results: Data demonstrated a significantly (r= ranging from 0.71 to 0.91; p: ranging from 0.001 to 0.003 by Pearson’s analysis respectively) correlation between MVD, MCDPT and C-KREC to each other. Conclusions: Published in vitro data suggest that tryptase induce angiogenesis in vascular endothelial cells and breast cancer cells lines. According to these data we shown that MVD, MCDPT and C-KREC paralleled to each other suggesting a role in in vivo breast cancer angiogenesis. In this context several tryptase inhibitors such as gabexate mesilate or nafamostat mesilate might be evaluated in clinical trials as a new antiangiogenetic approach.
Response to neoadjuvant chemotherapy as measured by PET predicts outcome after liver resection for colorectal metastases
Authors: T. J. Akhurst, M. Gonen, S. Tuorto, L. Schwartz, L. Brody, S. M. Larson, Y. Fong
Journal: Journal of Clinical Oncology (2006)

3056 Background: Patients with hepatic colorectal metastases are often treated with neoadjuvant chemotherapy prior to liver resection. FDG PET is a standard imaging modality for such patients. We have shown the amount of FDG uptake in liver metastases is reduced by recent chemotherapy (chemo) administration and this is associated with a reduction in FDG uptake mediated by a reduction in hexokinase activity. We sought to determine if the amount of FDG uptake in the hepatic colorectal metastasis post chemo correlates with survival and to compare the prognostic significance of this single biologic scan to standard clinical predictors of outcome. Methods: A group of 149 patients enrolled in a prospective clinical trial examining the efficacy of FDG PET imaging in patients undergoing hepatic resection of colorectal cancer metastases to the liver formed the dataset. The maximal SUV within the liver was recorded for each patient, and the median of those maximums was determined across the patient group. Patients were then stratified by the median SUV, by the presence or absence of any chemo within 6 months of PET and by the clinical risk score (CRS) (a standard score for prognosis based on five clinical parameter (nodal status of primary, disease-free interval before liver metastases, size of largest liver tumor, number of tumors, and CEA). Multivariate analysis (MVA) and hazard ratios of death (HRD) were assessed. Results: The median of maximal SUVs was 7.9. In MVA in the patients without recent chemo, the CRS≥3 was an excellent predictor of survival (HRD=2.53; p=0.008), while SUV&gt;8 was not (HRD=1.02; p=0.96). Conversely, in patients who had chemo within 6 months, SUV&gt;8 (HRD 3.34; p=0.03) was a much superior predictor of outcome than CRS≥3 (HRD=1.25; p=0.57). Conclusions: In those patients without recent chemo CRS is the best predictor of survival confirming the utility of this scoring system, In those patients who had had chemo within 6 months of PET prior to surgery PET SUV was the best predictor of survival. No significant financial relationships to disclose.
Inflammatory Pseudotumor of Intestine Mimicking Lymphoma on 18F-FDG PET/CT
Authors: Qianqian Xue, Weibing Miao
Journal: Clinical Nuclear Medicine (2020)

A 45-year-old man with suspected colonic malignancy was referred to F-FDG PET/CT for staging. PET/CT images showed segmental increased FDG uptake along the intestine with thickening of colonic wall, where no mass was obviously seen. Subsequently, left hemicolectomy and resection of partial small intestine were done. Histopathology of the resected specimen confirmed the diagnosis of inflammatory pseudotumor involving colon and small intestine. No recurrence was detected on follow-up CT images after 6 months. Although most of the previously reported intestinal inflammatory pseudotumor manifested as a mass, it should be considered as a differential diagnosis of FDG-avid segmental intestinal wall thickening.
POST-OPERATIVE ATRIAL FIBRILLATION FOLLOWING LIVER TRANSPLANTATION AND ASSOCIATION WITH ADVERSE CARDIOVASCULAR EVENTS
Authors: Anees Enayati, Anoop Koshy, Andrew W. Teh, Paul J. Gow, Hui-Chen Han, Benjamin Cailes, Laurence Weinberg, Adam Testro, Han Lim, H.M. Omar Farouque
Journal: Journal of the American College of Cardiology (2020)
Dissenting Opinions in Nutrition Research—Reply
Authors: John P. A. Ioannidis
Journal: JAMA (2020)

Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our Cookie Policy | Continue JAMA HomeNew OnlineCurrent IssueFor Authors Publications JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry (1919-1959) Podcasts Clinical Reviews Editors' Summary Medical News Author Interviews More JN Learning / CMESubscribeJobsInstitutions / LibrariansReprints & Permissions Terms of Use | Privacy Policy | Accessibility Statement 2023 American Medical Association. All Rights Reserved Search All JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Forum Archive JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry Input Search Term Sign In Individual Sign In Sign inCreate an Account Access through your institution Sign In Purchase Options: Buy this article Rent this article Subscribe to the JAMA journal
Long-term cancer survivorship care: On the radar screen?
Authors: Rutika Mehta, Rohit Jain, Lori Rhodes, Joseph Abraham, Kenneth David Miller
Journal: Journal of Clinical Oncology (2013)

e20567 Background: Long-term cancer survivors require comprehensive care. The purpose of this study was to describe how survivorship care fits into oncologists’ clinical time, and characterize long-term cancer survivors’ problems and oncology follow-up care. Methods: We abstracted 18,882 medical records of unique cancer patient visits during 2010 at a major NCI-designated cancer center and then evaluated survivor care for one week in April, 2010 to characterize how oncologists spend their clinical time. Finally, we selected three subgroups from the survivor population (n≈100 each) of survivors at 1-5 years, 6-10 years, and &gt;10 years after diagnosis. We collected demographic data, purpose of visit, cancer-specific information, late and long-term effects, and type of care delivered, including surveillance for recurrence, intervention, prevention, and coordination of care. Results: In the larger group of 18,882, only 14% of survivors were more than 10 years post-diagnosis. Approximately two-thirds of the survivors were women. Breast cancer survivors comprised 38%, and survivors of hematologic malignancies accounted for 21% of the population. During the one week studied, the majority of oncologists' patients (74%) were actively receiving treatment; only 5% of their patients were 5 or more years post-diagnosis. Second or secondary malignancies were noted in 8% of patients. Late and long-term effects were uncommon. Approximately 25% of survivors beyond five years were observed to have late effects due to cancer treatment, most common being fatigue, neurological endocrine, and cardiac. Of the 300 selected survivors, sixty-two percent received only surveillance care during their visit. Only 3% of these patients received an entire array of survivorship care that included surveillance, intervention, co-ordination and prevention. Conclusions: A small proportion of oncologists’ visits were with long-term cancer survivors (5-14%) of whom only 25% had late or long-term effects of cancer treatment so overall very few of office visits were with long-term survivors who had late and long-term complications. All visits involved surveillance for cancer recurrence but there was little focus on prevention, intervention, and coordination of care for cancer survivors.
THE HIDDEN CULPRIT: MYOCARDIAL BRIDGING AND RIGHT VENTRICULAR OUTFLOW TRACT OBSTRUCTION AS A CAUSE OF CHRONIC MYOCARDIAL ISCHEMIA
Authors: Bassam Ayoub, Jesus Diaz Vera, Aarti Anil Patel, Bibhu Mohanty, Xavier Prida
Journal: Journal of the American College of Cardiology (2020)
Phase I study of erlotinib (E) for solid tumors in patients with hepatic or renal dysfunction (HD or RD): CALGB 60101
Authors: A. A. Miller, D. J. Murry, D. R. Hollis, K. Owzar, L. D. Lewis, H. L. Kindler, J. L. Marshall, M. Villalona-Calero, M. J. Edelman, M. J. Ratain
Journal: Journal of Clinical Oncology (2006)

3026 Background: We sought to determine a tolerable dose and characterize the pharmacokinetics (PK) of E in patients with HD or RD. Methods: Patients with biopsy-proven solid tumors that commonly express EGFR, refractory to or without available standard therapy, performance status 0–2, and without biliary or renal obstruction were assigned to one of 3 cohorts (C): C1, AST ≥ 3 × ULN but no RD; C2, direct bilirubin 1–7 mg/dl but no RD; C3, creatinine 1.6–5.0 mg/dl but no HD. After slow accrual of 3 patients, an amended C1 for albumin &lt; 2.5 g/dl accrued 3 additional patients. E was administered po daily in groups of at least 3 evaluable patients in escalating doses of 50, 75, 100, 150 mg starting with 50 mg in HD and 75 mg in RD. Patients had to take E for at least 4 weeks to be considered evaluable for toxicity unless dose-limiting toxicity (DLT) occurred sooner. DLT was defined as: grade 4 neutrophils or platelets; bilirubin ≥ 1.5 × baseline in C1/2 and ≥ 2.5 × ULN in C3; creatinine ≥ 2 × ULN in C1/2 and ≥ 2.5 × baseline in C3; grade ≥ 3 nausea,vomiting,diarrhea despite optimal supportive care; or any other grade ≥ 3 non-hematologic toxicity. Blood samples were obtained before and 1, 2, 3, 4, 6, 24 hrs after the first dose. Plasma E concentrations were measured by HPLC. A 2-compartment PK model was used to estimate total clearance of E. Results: Between 12/01 and 5/05, 55 patients were accrued but 1 never started therapy: male/female, 34/20; white/black, 46/8; median age 56 (range, 39–78); PS 0/1/2, 12/25/17. The distribution of treated/evaluable patients was: 6/5 in C1, 30/16 (attrition due to progressive disease) in C2, and 18/18 in C3. DLT consisted of both total and direct bilirubin ≥ 1.5 × baseline in 3 patients: C1, 1 of 5 at 50 mg; C2, 2 of 6 at 100 mg. In C2, 1 of 7 patients had grade 4 diarrhea/dehydration and grade 3 hypotension at 75 mg. No DLT was encountered in C3 with 12 patients at 150 mg. Clearance (mean ± SD) was cohort-dependent: 1.51 ± 0.64 (C1), 2.36 ± 1.17 (C2), 4.34 ± 2.53 (C3) l/hr; 2-sided exact Kruskal-Wallis p &lt; 0.0006. Conclusions: Patients with RD tolerate 150 mg and appear to have normal clearance of E. Patients with HD should be treated at a reduced dose (i.e. 75 mg) consistent with their reduced clearance. [Table: see text]
A urine score for noninvasive accurate diagnosis and prediction of kidney transplant rejection
Authors: Joshua Y. C. Yang, Reuben D. Sarwal, Tara K. Sigdel, Izabella Damm, Ben Rosenbaum, Juliane M. Liberto, Chitranon Chan-On, José M. Arreola-Guerra, Josefina Alberu, Flavio Vincenti, Minnie M. Sarwal
Journal: Science Translational Medicine (2020)

Accurate and noninvasive monitoring of renal allograft posttransplant is essential for early detection of acute rejection (AR) and to affect the long-term survival of the transplant. We present the development and validation of a noninvasive, spot urine-based diagnostic assay based on measurements of six urinary DNA, protein, and metabolic biomarkers. The performance of this assay for detecting kidney injury in both native kidneys and renal allografts is presented on a cohort of 601 distinct urine samples. The urinary composite score enables diagnosis of AR, with a receiver-operator characteristic curve area under the curve of 0.99 and an accuracy of 96%. In addition, we demonstrate the clinical utility of this assay for predicting AR before a rise in the serum creatinine, enabling earlier detection of rejection than currently possible by standard of care tests. This noninvasive, sensitive, and quantitative approach is a robust and informative method for the rapid and routine monitoring of renal allografts.
DIRECT ORAL ANTICOAGULANTS VS. WARFARIN FOR NEW ONSET POST-CARDIAC SURGERY NON-VALVULAR ATRIAL FIBRILLATION
Authors: Victor Nauffal, Ludovic Trinquart, Asishana Osho, Thoralf M. Sundt, Steven Lubitz, Patrick T. Ellinor
Journal: Journal of the American College of Cardiology (2020)
A SINGLE NUCLEOTIDE POLYMORPHISM WITHIN THE RXRA GENE PREDICTS A FAVORABLE RESPONSE TO EXERCISE IN HEART FAILURE
Authors: Timothy Bryson, Joseph C. Debbs, Ruicong She, Hongsheng Gui, Jasmine A. Luzum, Nicole Zeld, Clinton A. Brawner, Steven J. Keteyian, Jonathan K. Ehrman, L Keoki Williams, David E. Lanfear
Journal: Journal of the American College of Cardiology (2020)
Analyses of the immunologically relevant gene transcript by qRT-PCR in primary cutaneous melanoma by the young and the elderly.
Authors: Upendra P. Hegde, Soheil Sam Dadras, Phil Kerr, Nitya Chakraborty, Jane grant-Kels, Bijay Mukherji
Journal: Journal of Clinical Oncology (2012)

e21135 Background: To understand the dynamics of anti tumor immune responses (IR) in the setting of the ageing immune system, we examined immunologically relevant gene transcripts in formalin fixed paraffin embedded (FFPE) primary cutaneous melanoma (PCM) samples derived from five young (age &lt;50 years) and five elderly (age &gt;or=70 years) patients by qRT-PCR. Methods: A total of 10 FFPE tumor blocks were collected between 2004-2007 of patients with PCM at the University of Connecticut Health Center. Total RNA was extracted from FFPE tissue sections and random primed cDNA was generated. Pre amplification using pooled Taqman assays and Universal PCR Master Mix (Applied Biosystems, USA) was performed for 14 cycles to ensure an adequate amount of starting material for qPCR. Using 15 ng total RNA, the quantification of human IR genes (IL-2, INFg, TNFa, TGFb1, IL-10, Foxp3, and IDO-1) and transcripts of succinate dehydrogenase (SDHA) (as endogenous control) was accomplished by qRT-PCR amplification of a cDNA using TaqMan Universal PCR Master Mix and TaqMan gene expressions assay probes. All reaction assays including that of SDHA were performed in triplicate on an ABI 7500 Fast system (Applied Biosystems). Cycle threshold (Ct) values for each mRNA were normalized to SDHA (DCT) and represented as RQ=2 -DCT . The average RQ was calculated for all ten samples in both cohorts and Student’s T-test was performed to evaluate the statistical significance of the IR gene expression. Results: While no significant difference of expression of Th1 cytokines (IL-2, IFNg, TNFa) or Th2/3 cytokines (IL-10, TGFb) could be detected within the two groups, FOXp3 expression was significantly decreased in PCM in the elderly. Conclusions: Our results suggest ageing may be associated with less regulatory responses in situ in PCM and that more expanded analyses of the nature of the IR in PCM are likely to provide information with implications on prognosis and immune based treatment options for elderly PCM subjects.
PROFILE OF PATIENTS DISCHARGED AGAINST MEDICAL ADVICE: IS THERE A COST?
Authors: Judith E. Mitchell, Roseann Chesler, Gregg C. Fonarow, Shuaiqi Zhang, Adam DeVore, Roland Matsouaka, Marilyn Fraser, Nai-Lun Chang, Nancy M. Albert, Larry A. Allen, Clyde W. Yancy
Journal: Journal of the American College of Cardiology (2020)
Opioid Prescribing in the Midst of Crisis — Myths and Realities
Authors: Michael L Barnett
Journal: New England Journal of Medicine (2020)

With the opioid-prescribing debate remaining hopelessly polarized — opioids are either industrially sponsored weapons of mass addiction or a misunderstood last hope for alleviating suffering — persistent myths contribute to overprescribing or underprescribing.
Treatment of Older Adults With Subclinical Hypothyroidism—Reply
Authors: Simon P. Mooijaart, Robert S. Du Puy
Journal: JAMA (2020)

Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our Cookie Policy | Continue JAMA HomeNew OnlineCurrent IssueFor Authors Publications JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry (1919-1959) Podcasts Clinical Reviews Editors' Summary Medical News Author Interviews More JN Learning / CMESubscribeJobsInstitutions / LibrariansReprints & Permissions Terms of Use | Privacy Policy | Accessibility Statement 2023 American Medical Association. All Rights Reserved Search All JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Forum Archive JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry Input Search Term Sign In Individual Sign In Sign inCreate an Account Access through your institution Sign In Purchase Options: Buy this article Rent this article Subscribe to the JAMA journal
TEMPORAL TRENDS AND OUTCOMES OF ELECTIVE AORTIC REPAIR AND ACUTE AORTIC SYNDROMES IN PATIENTS WITH BICUSPID AORTIC VALVES
Authors: Ayman Elbadawi, Ahmad Mahmoud, Islam Elgendy, Mohamed Omer, Gbolahan Ogunbayo, Ali Denktas, David Paniagua, Hani Jneid
Journal: Journal of the American College of Cardiology (2020)
ACTIVATED PLATELETS INDUCE ENDOTHELIAL CELL INFLAMMATORY RESPONSE IN PSORIASIS WHICH IS INHIBITED BY LOW-DOSE ASPIRIN
Authors: Michael Seth Garshick, Michael Tawil, Tessa Barrett, Charissa Salud, Michael Eppler, Angela Lee, Jose Scher, Andrea Neimann, Sanja Jelic, Nehal Mehta, Edward Fisher, James Krueger, Jeffrey Berger
Journal: Journal of the American College of Cardiology (2020)